Verona Pharma Plc News - VRP

Verona Pharma plc Correcting And Replacing -- Verona Pharma Reports Positive Phase 2 Results With Pmdi Formulation Of Ensifen...

LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc...

Verona Pharma plc Verona Pharma Reports Positive Phase 2 Results With Pmdi Formulation Of Ensifentrine In Copd

Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE...

Verona Pharma plc Verona Pharma Completes Enrollment In Pilot Study Of Pmdi Ensifentrine In U.S. Patients Hospitalized With C...

Top-line results expected in 2Q 2021 LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona...

Verona Pharma plc Verona Pharma To Present At H.C. Wainwright Virtualbioconnect Conference

LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...

Verona Pharma plc Verona Pharma Secures Up To $30 Million Debt Financing From Silicon Valley Bank

Non-dilutive capital to provide further financial flexibility LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc...

Verona Pharma plc Verona Pharma Announces November 2020 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...

AIM Cancellation - Verona Pharma PLC

AIM 30 October 2020 NOTICE 30/10/2020 7:00am NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON At the request of the Company the...

IN BRIEF: Verona Pharma Says Third Quarter Loss Widens

- clinical-stage biopharmaceutical company - Pretax loss in third quarter ended September 30 widens to USD22.2 millio ...

Verona Pharma plc Verona Pharma Plc Operational Update And Financial Results For The Three And Nine Months Ended September30,...

Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients...

Verona Pharma plc Verona Pharma Plc : Update On Aim Delisting

LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma" or the...

FTSE Russell Verona Pharma

FTSE Russell 23 October 2020 Verona Pharma (UK): Constituent Deletion Changes in FTSE UK Index Series 23 October 2020 Subject to the expected...

Verona Pharma plc Verona Pharma To Announce Interim Results For The Three And Nine Months Ended September 30, 2020 And Provid...

LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a...

Verona Pharma plc Verona Pharma To Present Phase 2b Copd Symptom And Quality Of Life Data With Ensifentrine At Chest 2020

Posters highlight ensifentrine's potential to provide rapid benefits LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona...

Verona Pharma plc Verona Pharma Initiates Phase 3 Clinical Trials With Nebulized Ensifentrine For The Maintenance Treatment O...

LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a...

IN BRIEF: Verona Pharma To Delist From AIM But Remain On Nasdaq

- clinical-stage biopharmaceutical company - To cancel trading of shares on AIM market. Last day of trading October 2 ...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Verona Pharma Plc (VRP)

Empower your portfolio: Real-time discussions and actionable trading ideas.

VRP News

Verona Pharma plc Correcting And Replacing -- Verona Pharma Reports Positive Phase 2 Results With Pmdi Formulation Of Ensifen...

Verona Pharma plc Verona Pharma Reports Positive Phase 2 Results With Pmdi Formulation Of Ensifentrine In Copd

Verona Pharma plc Verona Pharma Completes Enrollment In Pilot Study Of Pmdi Ensifentrine In U.S. Patients Hospitalized With C...

Verona Pharma plc Verona Pharma To Present At H.C. Wainwright Virtualbioconnect Conference

Verona Pharma plc Verona Pharma Secures Up To $30 Million Debt Financing From Silicon Valley Bank

Verona Pharma plc Verona Pharma Announces November 2020 Virtual Investor Conference Participation

AIM Cancellation - Verona Pharma PLC

IN BRIEF: Verona Pharma Says Third Quarter Loss Widens

Verona Pharma plc Verona Pharma Plc Operational Update And Financial Results For The Three And Nine Months Ended September30,...

Verona Pharma plc Verona Pharma Plc : Update On Aim Delisting

FTSE Russell Verona Pharma

Verona Pharma plc Verona Pharma To Announce Interim Results For The Three And Nine Months Ended September 30, 2020 And Provid...

Verona Pharma plc Verona Pharma To Present Phase 2b Copd Symptom And Quality Of Life Data With Ensifentrine At Chest 2020

Verona Pharma plc Verona Pharma Initiates Phase 3 Clinical Trials With Nebulized Ensifentrine For The Maintenance Treatment O...

IN BRIEF: Verona Pharma To Delist From AIM But Remain On Nasdaq

VRP Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Verona Pharma Plc (VRP) News

Verona Pharma Plc (VRP)

Empower your portfolio: Real-time discussions and actionable trading ideas.

VRP News

Verona Pharma plc Correcting And Replacing -- Verona Pharma Reports Positive Phase 2 Results With Pmdi Formulation Of Ensifen...

Verona Pharma plc Verona Pharma Reports Positive Phase 2 Results With Pmdi Formulation Of Ensifentrine In Copd

Verona Pharma plc Verona Pharma Completes Enrollment In Pilot Study Of Pmdi Ensifentrine In U.S. Patients Hospitalized With C...

Verona Pharma plc Verona Pharma To Present At H.C. Wainwright Virtualbioconnect Conference

Verona Pharma plc Verona Pharma Secures Up To $30 Million Debt Financing From Silicon Valley Bank

Verona Pharma plc Verona Pharma Announces November 2020 Virtual Investor Conference Participation

AIM Cancellation - Verona Pharma PLC

IN BRIEF: Verona Pharma Says Third Quarter Loss Widens

Verona Pharma plc Verona Pharma Plc Operational Update And Financial Results For The Three And Nine Months Ended September30,...

Verona Pharma plc Verona Pharma Plc : Update On Aim Delisting

FTSE Russell Verona Pharma

Verona Pharma plc Verona Pharma To Announce Interim Results For The Three And Nine Months Ended September 30, 2020 And Provid...

Verona Pharma plc Verona Pharma To Present Phase 2b Copd Symptom And Quality Of Life Data With Ensifentrine At Chest 2020

Verona Pharma plc Verona Pharma Initiates Phase 3 Clinical Trials With Nebulized Ensifentrine For The Maintenance Treatment O...

IN BRIEF: Verona Pharma To Delist From AIM But Remain On Nasdaq

VRP Discussion

Your Recent History